Autoantibodies against p16 protein-derived peptides may be a potential biomarker for non-small cell lung cancer

Tumor Biology

Volumn 35, Issue 3, 2014, Pages 2047-2051

  Zhang, Cong ^a   Ye, Leiguang ^b   Guan, Songlei ^a   Jin, Shunzi ^a   Wang, Weili ^a   Sun, Shilong ^a   Lee, Kuang Hui ^c   Wei, Jun ^d   Liu, Baogang ^b  

^a JILIN UNIVERSITY   (China)

^b HARBIN MEDICAL UNIVERSITY   (China)

^c Pei Ling Guan Si Hospital Hsin Fu Kuansi Township   (Taiwan)

^d UNIVERSITY OF THE HIGHLANDS AND ISLANDS   (United Kingdom)

Author keywords

Autoantibody; Biomarker; Lung cancer; p16 protein; Tumor immunity

Indexed keywords

AUTOANTIBODY; BIOLOGICAL MARKER; IMMUNOGLOBULIN A ANTIBODY; IMMUNOGLOBULIN G ANTIBODY; PEPTIDE DERIVATIVE; PROTEIN P16; TUMOR ANTIGEN;

ADULT; ANTIBODY PRODUCTION; ANTIGEN EXPRESSION; ARTICLE; CANCER PATIENT; CANCER PROGNOSIS; CANCER STAGING; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY;

AREA UNDER CURVE; AUTOANTIBODIES; AUTOANTIGENS; CARCINOMA, NON-SMALL-CELL LUNG; CYCLIN-DEPENDENT KINASE INHIBITOR P16; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; IMMUNOGLOBULIN G; LUNG NEOPLASMS; MALE; MIDDLE AGED; ROC CURVE; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL;

EID: 84898864625     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-013-1271-4     Document Type: Article

References (24)

1. Hall M, Bates S, Peters G. Evidence for different modes of action of cyclin-dependent kinase inhibitors: p15 and p16 bind to kinases, p21 and p27 bind to cyclins. Oncogene. 1995;11:1581-8.
2. Baldi A, De Luca A, Esposito V, Campioni M, Spugnini EP, Citro G. Tumor suppressors and cell-cycle proteins in lung cancer. Pathology Res Int. 2011. doi: 10.4061/2011/605042.
3. Johnson JL, Pillai S, Chellappan SP. Genetic and biochemical alterations in non-small cell lung cancer. Biochem Res Int. 2012. doi: 10.1155/2012/940405.
4. Matsushime H, Ewen ME, Strom DK, Kato JY, Hanks SK, Roussel MF, et al. Identification and properties of an atypical catalytic subunit (p34PSK-J3/cdk4) for mammalian D type G1 cyclins. Cell. 1992;71:323-45.
5. Tong J, Sun X, Cheng H, Zhao D, Ma J, Zhen Q, et al. Expression of p16 in non-small cell lung cancer and its prognostic significance: a meta-analysis of published literatures. Lung Cancer. 2011;74:155-63.
6. Zhao W, Huang CC, Otterson GA, Leon ME, Tang Y, Shilo K, et al. Altered p16(INK4) and RB1 expressions are associated with poor prognosis in patients with nonsmall cell lung cancer. J Oncol. 2012. doi: 10.1155/2012/957437.
7. Lou-Qian Z, Rong Y, Ming L, Xin Y, Feng J, Lin X. The prognostic value of epigenetic silencing of p16 gene in NSCLC patients: a systematic review and meta-analysis. PLoS One. 2013. doi: 10.1371/journal.pone.00549708.
8. Zhong L, Coe SP, Stromberg AJ, Khattar NH, Jett JR, Hirschowitz EA. Profiling tumor-associated antibodies for early detection of non-small cell lung cancer. J Thorac Oncol. 2005;1:513-9.
9. Reuschenbach M, von Knebel DM, Wentzensen N. A systematic review of humoral immune responses against tumor antigens. Cancer Immunol Immunother. 2009;58:1535-44.
10. Kobold S, Lütkens T, Cao Y, Bokemeyer C, Atanackovic D. Autoantibodies against tumor-related antigens: incidence and biologic significance. Hum Immunol. 2010;71:643-51.
11. Järås K, Anderson K. Autoantibodies in cancer: prognostic biomarkers and immune activation. Expert Rev Proteomics. 2011;8:577-89.
12. Liu W, Peng B, Lu YXW, Qian W, Zhang J-Y. Autoantibodies to tumor-associated antigens as biomarkers in cancer immunodiagnosis. Autoimmun Rev. 2011;10:331-5.
13. Chapman C, Murray A, Chakrabarti J, Thorpe A, Woolston C, Sahin U, et al. Autoantibodies in breast cancer: their use as an aid to early diagnosis. Ann Oncol. 2007;18:868-73.
14. Lam S, Boyle P, Healey GF, Maddison P, Peek L, Murray A, et al. EarlyCDT-Lung: an immunobiomarker test as an aid to early detection of lung cancer. Cancer Prev Res (Phila). 2011;4:1126-34.
15. Chapman CJ, Healey GF, Murray A, Boyle P, Robertson C, Peek LJ, et al. EarlyCDT®-Lung test: improved clinical utility through additional autoantibody assays. Tumour Biol. 2012;33:1319-26.
16. Ye H, Sun C, Ren P, Dai L, Peng B, Wang K, et al. Mini-array of multiple tumor-associated antigens (TAAs) in the immunodiagnosis of breast cancer. Oncol Lett. 2013;5:663-8.
17. Looi K, Megliorino R, Shi FD, Peng XX, Chen Y, Zhang JY. Humoral immune response to p16, a cyclin-dependent kinase inhibitor in human malignancies. Oncol Rep. 2006;16:1105-10.
18. Liu L, Liu N, Liu B, Yang Y, Zhang Q, Zhang W, et al. Are circulating autoantibodies to ABCC3 transporter a potential biomarker for lung cancer? J Cancer Res Clin Oncol. 2012;138:1737-42.
19. Ye L, Guan S, Zhang C, Lee K-H, Sun L, Wei J, et al. Circulating autoantibody to FOXP3 may be a potential biomarker for esophageal squamous cell carcinoma. Tumour Biol. 2013;34:1873-7.
20. Söllner J, Heinzel A, Summer G, Fechete R, Stipkovits L, Szathmary S, et al. Concept and application of a computational vaccinology workflow. Immunome Res. 2010;6 suppl 2:S7.
21. Wang P, Sidney J, Kim Y, Sette A, Lund O, Nielsen M, et al. Peptide binding predictions for HLA DR, DP and DQ molecules. BMC Bioinformatics. 2010. doi: 10.1186/1471-2105-11-568.
22. Lee CT, Capodieci P, Osman I, Fazzari M, Ferrara J, Scher HI, et al. Overexpression of the cyclin-dependent kinase inhibitor p16 is associated with tumor recurrence in human prostate cancer. Clin Cancer Res. 1999;5:977-83.
23. Chen YT, Scanlan MJ, Sahin U, Türeci O, Gure AO, Tsang S, et al. A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening. Proc Natl Acad Sci USA. 1997;94:1914-8.
24. Kanda M, Matthaei H, Wu J, Hong SM, Yu J, Borges M, et al. Presence of somatic mutations in most early-stage pancreatic intraepithelial neoplasia. Gastroenterology. 2012;142:730-3.